about
Lepirudin therapy for thrombotic complications in congenital afibrinogenaemiaCoiled-coil irregularities of the M1 protein structure promote M1-fibrinogen interaction and influence group A Streptococcus host cell interactions and virulence.Thromboelastography to monitor clotting/bleeding complications in patients treated with the molecular adsorbent recirculating systemTwo different hematocrit detection methods: different methods, different results?The IL-8 protease SpyCEP is detrimental for Group A Streptococcus host-cells interaction and biofilm formation.Increased neutrophil extracellular trap-mediated Staphylococcus aureus clearance through inhibition of nuclease activity by clindamycin and immunoglobulinDNase Sda1 allows invasive M1T1 Group A Streptococcus to prevent TLR9-dependent recognitionThe relationship between preoperative creatinine clearance and outcomes for patients undergoing liver transplantation: a retrospective observational study.Coagulation factor Xa cleaves protease-activated receptor-1 and mediates signaling dependent on binding to the endothelial protein C receptor.Streptococcal SpeB cleaved PAR-1 suppresses ERK phosphorylation and blunts thrombin-induced platelet aggregation.Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain.External validation of scores proposed for estimation of survival probability of patients with severe adult respiratory distress syndrome undergoing extracorporeal membrane oxygenation therapy: a retrospective studyRegulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).Importance of Toll-like receptor 9 in host defense against M1T1 group A Streptococcus infectionsProtease-activated receptor-1 cleaved at R46 mediates cytoprotective effects.Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications.Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells.Clindamycin Affects Group A Streptococcus Virulence Factors and Improves Clinical Outcome.ICU, hospital and one year mortality of patients suffering from solid or haematological malignancies.Effect of diagnosis related groups implementation on the intensive care unit of a Swiss tertiary hospital: a cohort study.Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1.Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseasesProtective signaling pathways of activated protein C in endothelial cellsSame quality - higher price? The paradox of allocation: the first national single center analysis after the implementation of the new Swiss transplantation law: the ICU viewThrombin cleaves and activates the protease-activated receptor 2 dependent on thrombomodulin co-receptor availabilityDynamic optic nerve sheath diameter changes upon moderate hyperventilation in patients with traumatic brain injuryStudents Supporting Critical Care - A contention plan to prevent the decompensation of ICUs in the COVID-19 pandemic:Translating Bjorn Ibsens' polio-lessons to modern times
P50
Q28168458-CC3885C8-C457-4FAD-97D1-6A460F721810Q30427641-CE697AFE-6D4F-4617-94DA-DB43652D8371Q33395093-CF7CF3AE-47E9-445A-86D2-D4231EA42CB3Q33538897-B255AFC9-9412-4658-8E64-085313B3E79EQ33877184-67062E56-C9CE-4920-99F8-AB4C4F1D662CQ33880228-07793D2E-915F-4704-911F-EEF02C940F04Q34311559-7EAAD249-36FE-466F-80E6-626D8627E2DEQ34587152-BEA86B48-9A8A-4890-B1B9-0952C672751FQ35010380-BC9EF06C-B4E0-44EC-8428-992833066079Q35053984-E9283662-B462-4321-8538-D67824D037A7Q35067413-9D3BA871-9F18-40F4-AA2B-5AB740CDEBD5Q35494858-CB18A39B-FB5F-4F7B-A833-4363E9E5404DQ35826597-04317E9B-422C-40CD-9B06-02372236FA3BQ36072078-364A178D-49E8-4C44-A238-E814ABDF00C3Q36166264-4060EC77-DA53-462D-B232-58CE1F792650Q36478253-E739EA39-AF61-4051-9672-EFB6581E61ECQ37237490-FEA38A00-4ACD-494D-95FD-D9D8598D69A8Q38481056-D03DCEE9-F32E-4641-AAB4-A37A13E07C27Q40278276-66ED6771-A7EF-4807-A6C2-A6DF8EE34559Q40650612-B44EC400-437B-4CEF-B3B9-705C78DB4D52Q44674176-28D6D8B9-8C14-4DF1-BE32-41C176277F21Q48103902-3F84E176-1DBD-4548-B9C2-11D860A81FDBQ51732026-76C76971-032C-4C8B-B2E1-0D6D326FC519Q64105617-C4FF7D46-DB72-4B0B-A756-CEB4C0ABF7C0Q80235401-1E37BE0A-B33C-4DEE-99E7-F40212209314Q82610495-E1087DB2-1711-4B1A-A40A-6CF57B8D85D9Q92302536-741C1784-0B65-4AEF-8295-822835C92DA4Q92944940-906332CF-E7E8-42CD-92EE-35E353E71ED2Q94567894-0A6CAF8C-A766-4CB2-814D-6F1AB8DED191
P50
description
researcher ORCID ID = 0000-0002-7058-4377
@en
wetenschapper
@nl
name
Reto A Schuepbach
@ast
Reto A Schuepbach
@en
Reto A Schuepbach
@es
Reto A Schuepbach
@nl
type
label
Reto A Schuepbach
@ast
Reto A Schuepbach
@en
Reto A Schuepbach
@es
Reto A Schuepbach
@nl
altLabel
Reto Schuepbach
@en
prefLabel
Reto A Schuepbach
@ast
Reto A Schuepbach
@en
Reto A Schuepbach
@es
Reto A Schuepbach
@nl
P1053
J-9737-2012
P106
P31
P496
0000-0002-7058-4377